Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06148285 · ClinicalTrials.gov registry record · NA
Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Ischemic Stroke Recovery (Pro00061930)
A NA study of Acute Ischemic Stroke, sponsored by LCMC Health.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06148285: Recruiting NA study of Acute Ischemic Stroke, sponsored by LCMC Health.
NCT06148285 is a NA study of Acute Ischemic Stroke that is actively recruiting participants, run by LCMC Health. The registered enrollment target is 120 participants, below the 347-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06148285, a NA study of Acute Ischemic Stroke, is actively recruiting participants, sponsored by LCMC Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will critically examine the feasibility, safety and efficacy of HBOT during inpatient rehabilitation (IPR) after acute ischemic stroke measured by non-disruption of 3 hours of daily therapy, frequency of neurological deterioration or complications (seizure, hemorrhage, brain edema), and functional communication, activities of daily living (ADLs) and mobility.
Primary Outcome
Difference in the total, motor, and cognitive functional independence measure (FIM) scores between the three arms at the end of respective treatment blocks (2 - week period). Additional analyses for change in the FIM score will also be conducted.
Conditions Studied
Interventions
- DEVICE Hyperbaric Oxygen Therapy
Study Locations (1)
Louisiana
- Touro Infirmary New Orleans - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-05-24 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06148285 shows while recruiting
NCT06148285 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 347-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which Hyperbaric Oxygen Therapy is the first listed.
NCT06148285 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT06148285 about?
NCT06148285 is a clinical study titled "Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Ischemic Stroke Recovery (Pro00061930)". This study will critically examine the feasibility, safety and efficacy of HBOT during inpatient rehabilitation (IPR) after acute ischemic stroke measured by non-disruption of 3 hours of daily therapy, frequency of neurological deterioration or complications (seizure, hemorrhage, brain edema), and f...
What is the current status of trial NCT06148285?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2022-05-24. Estimated completion is 2026-12-31.
What conditions does trial NCT06148285 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT06148285?
The interventions under investigation include: Hyperbaric Oxygen Therapy (DEVICE).
Who is sponsoring clinical trial NCT06148285?
This trial is sponsored by LCMC Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06148285 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06148285's enrollment target sits among peer trials
120 17th of 25 higher than 8 of 25 other Acute Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke
RECRUITING · NA
-
The Pivotal Study of RapidPulseTM Aspiration System
RECRUITING · NA
-
An EFS to Evaluate the CGuard Prime™ Carotid Stent in Acute Ischemic Stroke
ACTIVE NOT RECRUITING · NA
-
Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI
ACTIVE NOT RECRUITING · NA
-
EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial)
ACTIVE NOT RECRUITING · NA
-
Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI